Bluebird bio's exit from Europe last year signals rough seas ahead for gene therapy developers, who are trying to gain market access for their products. Evidently, bluebird bio couldn’t strike deals with European payers for its EMA-approved gene therapies, Zynteglo (beti-cel) and Skysona (eli-cel).
Subscribe to:
Post Comments (Atom)
< + > What Drives EHR Innovation in Prescription Management and How Technology Can Help
Few patients take a paper prescription down to the local pharmacy any more. The modern era of prescribing is shockingly complex and getting ...
-
As I’m sure you know, times are tough. Wages have largely remained the same while prices have risen across the board – and healthcare is no ...
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
No comments:
Post a Comment